

## Special Issue

# Biomarkers and Early Detection Strategies of Ovarian Cancer

### Message from the Guest Editors

Ovarian cancer (OC) is the deadliest of all gynecologic malignancies. The 5-year relative survival rate is 92.4% if the disease is diagnosed at the localized (early) stage; however, this decreases to 31.5% when diagnosed at the distant (late) stage. Approximately 70% of patients with OC are diagnosed at advanced stages, which are associated with poor prognosis and low survival rate.

Early detection is critical to achieve a high cure rate for OC patients. Biomarkers have been rapidly emerging for OC, e.g., CA125, HE4, miR-126, and miR-200a. However, an effective strategy for OC early detection is not available currently.

The manuscripts that will be considered for this Special Issue include original research articles and reviews. Studies conducted using cell/tissue culture systems, vertebrate animal models, or human subjects are welcome. The goal is to increase our knowledge of molecular mechanisms, cellular events, and pathological parameters in OC development and metastases. Findings will provide valuable insights into OC pathology, facilitating diagnosis and treatment and the development of early-detection strategies.

---

### Guest Editors

Dr. Fuhua Xu  
Dr. Tanja Pejovic  
Dr. Jing Xu

---

### Deadline for manuscript submissions

closed (15 May 2024)

G C A T  
T A C G  
G C A T

## Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/si/189090](https://mdpi.com/si/189090)

*Genes*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[genes@mdpi.com](mailto:genes@mdpi.com)

[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



G C A T  
T A C G  
G C A T

# Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



## About the Journal

### Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

---

### Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan  
Experimental Cancer Therapeutics, The University of Alabama at  
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-  
2182, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2  
(Genetics (clinical))